RT Journal Article
SR Electronic
T1 Computational Modeling of Ovarian Cancer Reveals Optimal Strategies for Therapy and Screening
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 19009712
DO 10.1101/19009712
A1 Gu, Shengqing S
A1 Lheureux, Stephanie
A1 Sayad, Azin
A1 Cybulska, Paulina
A1 Ben-David Hogen, Liat
A1 Vyarvelska, Iryna
A1 Tu, Dongsheng
A1 Parulekar, Wendy
A1 Nankivell, Matthew
A1 Kehoe, Sean
A1 Chi, Dennis
A1 Levine, Douglas A
A1 Bernardini, Marcus Q
A1 Rosen, Barry
A1 Oza, Amit
A1 Neel, Benjamin G
YR 2020
UL http://medrxiv.org/content/early/2020/06/09/19009712.abstract
AB High-grade serous tubo-ovarian carcinoma (HGSC) is a major cause of cancer-related death. Whether treatment order - primary debulking surgery followed by adjuvant chemotherapy (PDS) or neoadjuvant chemotherapy with interval surgery (NACT) - affects outcome is controversial. We developed a mathematical framework that holds for hierarchical or stochastic models of tumor initiation and reproduces HGSC clinical course. After estimating parameter values, we infer that most patients harbor chemo-resistant HGSC cells at diagnosis, and that if complete debulking (<1 mm residual tumor) can be achieved, PDS is superior to NACT due to better depletion of resistant cells. We further predict that earlier diagnosis of primary HGSC, followed by complete debulking, could improve survival, but its benefit in relapsed patients is likely to be limited. Our predictions are supported by primary clinical data from multiple cohorts. Our results have clear implications for these key issues in HGSC management.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by grants from the Terry Fox Foundation (TFPPG 020003), National Cancer Institute (R37 49152), and Department of Defense (60167542 104703 A) (to B.G.N.), and a DCA Award from University of Toronto (to S.G.).Author DeclarationsAll relevant ethical guidelines have been followed and any necessary IRB and/or ethics committee approvals have been obtained.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesAny clinical trials involved have been registered with an ICMJE-approved registry such as ClinicalTrials.gov and the trial ID is included in the manuscript.YesI have followed all appropriate research reporting guidelines and uploaded the relevant Equator, ICMJE or other checklist(s) as supplementary files, if applicable.YesAll data were acquired from published clinical trials or retrospective studies.